Annual reportSep 2026
Sep 2026 · Copy of Newspaper Publication 8 Sep - 9th AGM on 30 Sep 2026 via VC/OAVM; annual report dispatched, e-voting details published.
Source: Nse
QMS Medical Allied Services Ltd. (QMSMEDI)
SME CapPharma stocks · SME cap · NSE
QMS Medical Allied Services Ltd. operates in Services, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 12:52 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
77BullishSMA20 +18.8% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 61
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
QMSMEDID candles · FIT view+89.7%Latest close ₹171.40 on 2026-10-21
Bar
-4.0%
RSI
45
MACD hist
-4.42
52W pos
69%
2026-10-21O ₹178.60H ₹183.75L ₹170.10C ₹171.40Vol 23,025 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
QMSMEDINifty PharmaNifty 500
- QMSMEDI
- +60.2%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +66.7 pp
Chart stats
21 Oct 2026- From 52W high
- -20.9%
- 52W range position
- 69%
- ATR (14)
- 6.1%
- Volume vs 20D
- 0.29x
- Avg traded value
- ₹1.6 Cr
- 20D price channel
- ₹167 - ₹216.8
₹216.8
₹69 - ₹216.8
₹10.4
Latest completed session
20-session average
57.7% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST32
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent85
Revenue +22.3% · PAT +25.3% YoY
Technical
Bullish77
Price trend and sector-relative-strength timing.
Valuation
Legacy model+31.5%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence56
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 85/100Rev +22% YoY · PAT +25% YoY · margin expansion · +28% QoQ
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹56.9 Cr | +22.3% | +28.0% |
| EBITDA | ₹8.3 Cr | +27.1% | +40.4% |
| Operating margin | 14.6% | +55 bps | +128 bps |
| PAT | ₹4 Cr | +25.3% | +110.6% |
| PAT margin | 7.0% | +16 bps | +273 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 33.40
- P/B
- 3.45
- EV/EBITDA
- 13.12
- Market Cap
- 359.00Cr
Profitability
- ROE
- 10.40%
- ROCE
- 12.90%
- ROA
- 6.10%
- Dividend Y
- 0.27%
Growth (CAGR)
- Revenue 5Y
- 14.47%
- EPS 5Y
- 13.04%
- Revenue 3Y
- 11.00%
- EPS 3Y
- 11.00%
Balance Sheet
- Debt/Equity
- 0.71
- Interest Coverage
- 4.00×
- Altman Z
- 4.00
- Book Value
- 53.90
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- 19.00 Cr
- EPS TTM
- 5.56
Shareholding
- Promoter Hold
- 68.11%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 79%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 56.9+28.0% vs prev
Net Profit
₹ CrLatest: 4.0+110.6% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 45. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~15.8% over last month) — short-term momentum positive.
- RSI(14) at 45 — falling, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 21% off 52W high · 149% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & peers
U-Score 32 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 32 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation9/30
Growth11/25
Quality2/20
Balance Sheet7/15
Cash Flow1/10
Piotroski
8/9 (+5)
Penalties
-3
Raw sum
32
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
32/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 31.5%.
- Balance sheet contributes 7/15 to the score.
Main drags
- Penalty bucket subtracts 3 points.
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
33.4
PB
3.5
EV/EBITDA
13.1
ROE
10.4%
ROCE
12.9%
FCF Yield
—
Debt/Equity
0.7
MoS
+31.5%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
32
Previous: 32
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+31.5%
Previous: +29.3%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
32
32
32
32
32
32
32
32
32
32
32
32
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹82.12
-108.7% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹250.2
+31.5% MoS
PEG
2.73
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
MEDISTEP
SME
Medistep Healthcare Ltd.
Healthcare Services
match 156
69
5.1
21.7%
+89%
UNDERVALUED
MADHAVBAUG
SME
Vaidya Sane Ayurved Laboratories Ltd.
Healthcare Services
match 133
51
18.8
12.0%
+59%
FAIR VALUE
NEPHROCARE
SME
Nephro Care India Ltd.
Healthcare Services
match 132
14
27.7
4.9%
-464%
OVERVALUED
SANGANI
SME
Sangani Hospitals Ltd.
Healthcare Services
match 132
29
26.2
7.8%
-20%
OVERVALUED
CHANDAN
SME
Chandan Healthcare Ltd.
Healthcare Services
match 132
58
22.2
19.8%
+50%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
QMS Medical Allied Services Ltd. operates in Services, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
56Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 18th percentile of the scored universe and 13th percentile within Pharma. Main check: results consistency is weak at 34/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
18 docs text-extracted · 9 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
18th percentile
overall median 67 · Pharma: 13th pctile, median 70 · SME: 19th pctile, median 64
Evidence depth
Financial-only
18 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
68
acceptable · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
34
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 68.1%.
- ▸Promoter pledge is zero.
Trust risks
- ▸Promoter holding fell 5.6%.
- ▸Only 0 years of positive FCF.
- ▸1/4 latest quarters had positive YoY PAT growth.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching QMS Medical Allied Services Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Investor presentationJun 2026
Jun 2026 · Analysts/Institutional Investor Meet/Con. Call Updates 4 June 2026 - QMS Medical released Q4/FY26 investor presentation; FY26 revenue rose 11% to ₹172.9 crore, PAT fell 13% to ₹11.9 crore.
Source: Nse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
Concall transcriptNov 2024
Nov 2024 · Transcript
Source: Nse
Investor presentationNov 2024
Nov 2024 · PPT
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.